findmyKOL

Gabriel Contreras, MD, MPH

Enriched profile

Professor of Clinical Medicine, Katz Family Division of Nephrology and Hypertension · University of Miami Miller School of Medicine

ORCIDNone on fileNPI
Region🇺🇸 Miami, FL · Southeast · United StatesSpecialtyNephrologyFocusNephrology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2023Online presenceverified 2026Payments2021–2025NIH funding2001–2007Why? →

Gabriel Contreras is Professor of Clinical Medicine, Katz Family Division of Nephrology and Hypertension at University of Miami Miller School of Medicine. ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 31 Aug 2026

Gabriel Nicolas Contreras Martin, MD, MPH, is Professor of Clinical Medicine, Katz Family Division of Nephrology and Hypertension at University of Miami Miller School of Medicine, Department of Medicine, Katz Family Division of Nephrology and Hypertension. The public record shows 146 publications with 11,650 citations (h-index 49), centered on Nephrology. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 14 companies, 1 NIH-funded awards (2001–2007).

  • Top research focus: Nephrology
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 14 companies

Generated from the cited public record · current as of 31 Aug 2026. Every fact links its source below.

Research focus

OpenAlex concept fingerprint
Nephrology

Drugs & molecules

across trials, industry payments and publications
Gazyvageneric · ObinutuzumabClinical trialsIndustry payments10PublicationsBenlystageneric · BelimumabClinical trialsIndustry payments6PublicationsVelphorogeneric · Sucroferric oxyhydroxideClinical trialsIndustry payments6Publications

Works with

trial sponsors and companies reporting payments
Genentech, Inc.Clinical trialsIndustry payments19GlaxoSmithKline, LLC.Clinical trialsIndustry payments7Fresenius USA Marketing, Inc.Clinical trialsIndustry payments6

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
49h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
14companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2001–2007

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 31 Aug 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 31 Aug 2026

14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    74.4%
    Angiotensin receptor blocker (ARB)23.1%
    Losartan Potassium41%Telmisartan29%Valsartan12%Olmesartan Medoxomil10%Telmisartan-Amlodipine6%Candesartan Cilexetil3%
    Part D<11 patients
    Calcium channel blocker18.3%
    Amlodipine Besylate87%Nifedipine Er7%Amlodipine-Valsartan6%
    Part D<11 patients
  • Metabolism & gastrointestinal

    13.4%
    SGLT2 inhibitor9%
    Farxiga73%Jardiance27%
    Part D30 patients
    Vitamin D3 Analog1.6%
    Calcitriol100%
    Part D<11 patients
  • Genitourinary & hormones

    2.7%
    Progestin1.3%
    Megestrol Acetate100%
    Part D<11 patients
    alpha-Adrenergic Blocker1.3%
    Tamsulosin Hcl100%
    Part D<11 patients
7 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)54.5% facility · 45.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 31 Aug 2026

1 NIH research award on record, funded 20012007 per NIH RePORTER. The latest:

4 more award records behind the reveal.Reveal →

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 31 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/gabriel-contreras-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Other

    med.miami.edu/faculty/gabriel-nicolas-contreras-md-mph

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu
  • ResearchGate

    miami.pure.elsevier.com/en/persons/gabriel-contreras

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →miami.pure.elsevier.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 31 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Critical Care Medicine Fellowship

    Jackson Memorial Hospital

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.umiamihealth.org
  • Nephrology Fellowship

    Jackson Memorial Hospital

    1994
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.umiamihealth.org
  • Internal Medicine Internship and Residency

    Harlem Hospital Center of Columbia University

    1992
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.umiamihealth.org
  • MD

    Universidad Nacional Autónoma de México

    1989
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu
  • MPH

    Master of Public Health

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu
  • Board Certified

    Nephrology, American Board of Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.umiamihealth.org

Editorial & leadership roles

journal and society appointments
  • Chair

    independent Data Monitoring Committee for participant safety in 2 clinical trials of new lupus nephritis treatments sponsored by Genentech

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jrheum.org
  • Site Principal Investigator

    African American Study of Kidney Disease and Hypertension (AASK) trial-cohort at University of Miami

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com
  • Site Principal Investigator

    Systolic Blood Pressure Intervention Trial (SPRINT), NIH-funded

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Author

    invited Editorial "Lupus Nephritis Treatment Strategies," The Journal of Rheumatology

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jrheum.org

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.